MedEquities Realty Trust Inc (MRT) Receives $12.80 Consensus Price Target from Analysts

Shares of MedEquities Realty Trust Inc (NYSE:MRT) have received a consensus rating of “Buy” from the eight brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and five have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $12.80.

A number of analysts have weighed in on the stock. ValuEngine raised shares of MedEquities Realty Trust from a “hold” rating to a “buy” rating in a report on Friday, December 1st. Zacks Investment Research raised shares of MedEquities Realty Trust from a “sell” rating to a “hold” rating and set a $12.00 target price on the stock in a report on Wednesday, November 15th. B. Riley reaffirmed a “buy” rating on shares of MedEquities Realty Trust in a report on Wednesday, November 8th. KeyCorp set a $13.00 price objective on shares of MedEquities Realty Trust and gave the stock a “buy” rating in a report on Sunday, October 29th. Finally, Capital One Financial reaffirmed an “equal weight” rating on shares of MedEquities Realty Trust in a report on Sunday, October 22nd.

Shares of MedEquities Realty Trust (NYSE:MRT) traded up $0.03 during trading hours on Monday, hitting $11.08. 389,115 shares of the company’s stock were exchanged, compared to its average volume of 156,523. The firm has a market capitalization of $350.90, a PE ratio of 10.05 and a beta of -0.75. MedEquities Realty Trust has a 52 week low of $10.06 and a 52 week high of $13.06.

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, November 29th. Investors of record on Wednesday, November 15th were issued a $0.21 dividend. The ex-dividend date was Tuesday, November 14th. This represents a $0.84 dividend on an annualized basis and a dividend yield of 7.58%. MedEquities Realty Trust’s dividend payout ratio (DPR) is presently 210.01%.

In other news, CEO John W. Mcroberts acquired 18,000 shares of the company’s stock in a transaction that occurred on Friday, November 17th. The shares were acquired at an average price of $10.74 per share, with a total value of $193,320.00. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Randy L. Churchey acquired 5,300 shares of the company’s stock in a transaction that occurred on Monday, November 20th. The stock was purchased at an average cost of $10.87 per share, for a total transaction of $57,611.00. Following the acquisition, the director now owns 46,776 shares in the company, valued at $508,455.12. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 23,600 shares of company stock worth $254,129. Corporate insiders own 2.50% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. JPMorgan Chase & Co. bought a new position in MedEquities Realty Trust in the 3rd quarter valued at about $118,000. Raymond James Financial Services Advisors Inc. bought a new position in MedEquities Realty Trust in the 2nd quarter valued at about $154,000. Acadian Asset Management LLC bought a new position in MedEquities Realty Trust in the 2nd quarter valued at about $175,000. Alliancebernstein L.P. bought a new position in MedEquities Realty Trust in the 2nd quarter valued at about $175,000. Finally, Cubist Systematic Strategies LLC bought a new position in MedEquities Realty Trust in the 3rd quarter valued at about $177,000. 93.19% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2017/12/14/medequities-realty-trust-inc-mrt-receives-12-80-consensus-price-target-from-analysts.html.

About MedEquities Realty Trust

MedEquities Realty Trust, Inc is a real estate investment trust (REIT). The Company invests in a diversified mix of healthcare properties and healthcare-related real estate debt investments. The Company invests primarily in real estate across the acute and post-acute spectrum of care. It focuses on investing in various types of healthcare properties, including acute care hospitals; skilled nursing facilities; short-stay surgical and specialty hospitals, which focus on orthopedic, heart and other dedicated surgeries and specialty procedures; dedicated specialty hospitals, such as inpatient rehabilitation facilities, long-term acute care hospitals and facilities providing psychiatric care; physician clinics; diagnostic facilities; outpatient surgery centers, and facilities that support these services, such as medical office buildings.

Analyst Recommendations for MedEquities Realty Trust (NYSE:MRT)

Receive News & Ratings for MedEquities Realty Trust Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MedEquities Realty Trust and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply